TuHURA Biosciences, Inc./NV
HURANasdaq
$2.25
↑ +1.4%Jul 17 close · end-of-day
Price
1Y↓ -4.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$135.0M
Enterprise Value
$128.7M
P/E
—
P/S
—
P/B
5.8
EV/EBITDA
—
PEG
—
FCF Yield
-20.3%
Dividend Yield
—
Revenue (TTM)
$0.00
Net Income (TTM)
-$31.9M
Free Cash Flow (TTM)
-$27.4M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-137.4%
ROIC
—
Debt / Equity
—
Net Cash
$6.3M
Return 1Y
-11.1%
Company profile
TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.
- CEO
- James Bianco
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- Florida
- Website
- tuhurabio.com
Earnings
HURA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00—
Diluted EPS-$0.13↓ -13.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2023 | FY2024 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | — | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — |
| Net income | -$38.3M | -$22.7M | -$14.6M | -$15.0M | -$8.3M | -$23.0M | -$31.0M |
| Diluted EPS | — | — | — | -$2.47 | — | -$1.21 | -$0.63 |
| Operating cash flow | -$18.9M | -$20.4M | -$11.9M | -$12.0M | -$7.2M | -$14.7M | -$27.6M |
| Free cash flow | — | -$20.6M | — | -$12.0M | — | -$14.8M | -$27.7M |
| Gross margin | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | -$5.3M | -$5.6M | -$7.3M | -$6.7M | -$9.5M | -$7.1M | -$7.7M | -$7.5M |
| Diluted EPS | -$0.43 | -$0.54 | $0.16 | -$0.15 | -$0.21 | -$0.14 | -$0.13 | -$0.13 |
| Operating cash flow | -$5.1M | -$1.9M | -$3.9M | -$4.7M | -$6.2M | -$11.1M | -$5.6M | -$4.4M |
| Free cash flow | — | -$1.9M | — | -$4.8M | -$6.3M | -$11.1M | -$5.6M | -$4.5M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-28 | BIANCO JAMES A· Chief Executive Officer | Gift | 150,000 | $0.00 | $0.00 | filing |
Latest 1 transaction.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.